Small-scale growth Target mid-market drug screening buyers in community hospitals and clinics transitioning to CLIA Waived tests, highlighting UCP Biosciences' FDA inspected cGMP facility and ISO certification to bolster confidence in quality and compliance.

Affordability focus Leverage their <$1M revenue profile to position cost-effective, scalable test kits for smaller labs or regional networks, emphasizing quick results and ease of use to drive adoption among budget-conscious buyers.

Expansion opportunities Identify potential distributors or regional partners (e.g., independent labs, urgent care networks) to broaden kit reach, citing the 500 test kit sale to Herington Hospital as a precedent for mid-volume deployments.

Technology leverage Offer bundled solutions that integrate with customers’ existing digital ecosystems (WordPress, WooCommerce, JotForm, Microsoft 365) for seamless ordering, reporting, and compliance documentation to reduce procurement friction.

Competitive positioning Differentiate from larger peers by emphasizing flexibility of 15 CLIA Waived tests in any combination, rapid on-site results, and the ability to serve smaller labs that may be overlooked by bigger manufacturers.